Forty Seven Inc

Forty Seven, Inc. is a clinical-stage immuno-oncology company that is developing therapies targeting cancer immune evasion pathways based on technology licensed from Stanford University. Forty Seven's lead program, 5F9, is a monoclonal antibody against the CD47 receptor, a ''don't eat me'' signal that cancer cells commandeer to avoid being ingested by macrophages. This antibody is currently being evaluated in six clinical studies in patients with solid tumors, acute myeloid leukemia, non-Hodgkin's lymphoma and colorectal carcinoma.

TG Therapeutics

These two small-cap biopharmas have promising early-stage drug candidates that could take them far if all goes according to plan.

2 Small-Cap  Stocks With Big-Cap Potential

Forty Seven: Early Indications Suggest Magrolimab Could Be A Winner

bluebird bio

Bristol-Myers

Johnson & Johnson

uniQure

The potential to reshape treatment of blood cancer and disorders could mean big bucks for these companies.

The Top Biotech Stocks to Watch Following ASH 2019

MENLO PARK, Calif., Dec.  16, 2019  (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced the closing of its previously announced public offering of 5,589,000 shares of common stock, including 729,000 shares sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares. Gross proceeds from the offering, before underwriting discounts and commissions and offering expenses, were approximately $195.6 million.

Forty Seven, Inc. Announces Closing of Underwritten Public Offering and Exercise in Full of Option to Purchase Additional Shares

The biopharma announced the pricing of a public stock offering.

Here's Why Forty Seven Stock Gained as Much as 18.5% Today

MENLO PARK, Calif., Dec.  11, 2019  (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced the pricing of its previously announced underwritten public offering of 4,860,000 shares of its common stock at a price to the public of $35.00 per share.  Gross proceeds to Forty Seven from the offering are expected to be $170.1 million, before deducting underwriting discounts and commissions and estimated offering expenses.  All of the shares of common stock are being offered by Forty Seven. In addition, Forty Seven has granted the underwriters a 30-day option to purchase up to 729,000 of additional shares of common stock at the public offering price, less underwriting discounts and commissions.  The offering is expected to close on December 16, 2019, subject to customary closing conditions.

Forty Seven, Inc. Prices Underwritten Public Offering of 4,860,000 Shares of Common Stock

MENLO PARK, Calif., Dec.  11, 2019  (GLOBE NEWSWIRE) -- Forty Seven, Inc. (Nasdaq: FTSV), a clinical stage immuno-oncology company, today announced that it has commenced an underwritten public offering of $140,000,000 of shares of its common stock. All of the shares of common stock are being offered by Forty Seven. In connection with this offering, Forty Seven expects to grant the underwriters a 30-day option to purchase up to $21,000,000 of additional shares of common stock.

Forty Seven, Inc. Announces Proposed Underwritten Public Offering of Common Stock

Precision Biosciences

Mustang Bio

Roche Holding AG

The American Society of Hematology's 61st annual meeting is underway in Orlando, Florida.

5 Stocks Moving On ASH Presentations

Forty Seven jumped on promising data for its lead drug candidate.

This Small-Cap Biotech Rose as Much as 98.3% Today

Forty Seven's (FTSV) CEO Mark McCamish on Q3 2019 Results - Earnings Call Transcript

Forty Seven to Host Investor Event and Webcast on December 9, 2019 Forty Seven to Host Investor Event and Webcast on December 9, 2019

Forty Seven, Inc. to Present New Clinical and Preclinical Data on Magrolimab and FSI-174 at 61st ASH Annual Meeting

MENLO PARK, Calif., Sept.  27, 2019  (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that Mark McCamish, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2019 Cantor Global Healthcare Conference on Friday, October 4, 2019 at 8:20 a.m. ET in New York, NY.

Forty Seven Inc. to Present at 2019 Cantor Global Healthcare Conference

Catalyst Pharmaceuticals

EyePoint Pharmaceuticals

These three biotech stocks could be great buys this month.

3 Top Biotech Stocks to Buy in September

MENLO PARK, Calif., Sept.  03, 2019  (GLOBE NEWSWIRE) -- Forty Seven Inc. (NASDAQ:FTSV), a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that Mark McCamish, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Morgan Stanley 17th Annual Global Healthcare Conference on Tuesday, September 10, 2019 at 2:55 p.m. ET in New York, NY.

Forty Seven Inc. to Present at Morgan Stanley 17th Annual Global Healthcare Conference

MENLO PARK, Calif., Sept.  03, 2019  (GLOBE NEWSWIRE) -- Forty Seven, Inc., a clinical-stage, immuno-oncology company focused on developing therapies to activate macrophages in the fight against cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to magrolimab (formerly known as 5F9) for the treatment of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Magrolimab is a monoclonal antibody against CD47 that is designed to block the “don’t eat me” signal used by cancer cells to avoid being ingested by macrophages.

Forty Seven, Inc. Granted Fast Track Designation for Magrolimab (5F9) for the Treatment of Myelodysplastic Syndrome and Acute Myeloid Leukemia

Forty Seven has been able to obtain substantial funding from the world's largest voluntary health organization Leukemia & Lymphoma Society to fund 5F9 to treat patients with myelodysplastic syndrome.

Forty Seven Gets Funding To Move Promising Treatment Forward Towards Potential Registration Study

Forty Seven, Inc. (FTSV) CEO Mark McCamish on Q2 2019 Results - Earnings Call Transcript

Forty Seven (NASDAQ: FTSV) and Ono Pharmaceutical have inked an exclusive license agreement for the development, manufacture and commercialization of 5F9, Forty Seven’s monoclonal antibody against CD47.

Forty Seven Wins Exclusive License Deal For 5F9

Forty Seven's (FTSV) CEO Mark McCamish on Q1 2019 Results - Earnings Call Transcript

Forty Seven, Inc.'s (FTSV) CEO Mark McCamish on Q4 2018 Results - Earnings Call Transcript

News for Forty Seven Inc Stock (FTSV)